Eledon Pharmaceuticals, Inc. ELDN
At closeNov 4, 2026, 4:00 PM EST
After hours · Nov 4, 4:00 PM ET
- YTD
- +78.81%
- 1 year
- -35.10%
- Market cap
- 219.41M
- EPS (ttm)
- -0.90
- Shares out
- 59.74M
- Forward P/E
- -3.49
- YTD return
- +78.81%
- 1-year return
- -35.10%
- Volume
- 500.34K
- Avg volume
- 910.28K
- Open
- 2.70
- Previous close
- 2.62
- Day's range
- 2.69 – 2.84
- 52-week range
- 1.35 – 4.49
- Price target
- 12.50 (+363.0%)
2Y -2.29 (-45.89%)
Key statistics
- Enterprise value
- 182.77M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 2.27
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -23.20M
- Total cash
- 78.19M
- Total debt
- 501.00K
- Return on equity
- -25.36%
- Short % of float
- 1.29%
- 50-day average
- 4.12
- 200-day average
- 2.88
Analyst view
- Target (low)
- 7.00
- Target (mean)
- 12.50
- Target (high)
- 20.50
- Strong buy1
- Buy5
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.30333.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.30 | -0.32 | -0.02 | -6.67% |
| Aug 19, 2024 | Jun 1, 2024 | -0.31 | -0.32 | -0.01 | -3.23% |
| May 9, 2024 | Mar 1, 2024 | -0.37 | -0.34 | +0.03 | +8.11% |
| Mar 28, 2024 | Dec 1, 2023 | -0.38 | -0.29 | +0.09 | +23.68% |
| Nov 9, 2023 | Sep 1, 2023 | -0.41 | -0.35 | +0.06 | +14.63% |
| Aug 10, 2023 | Jun 1, 2023 | -0.47 | -0.40 | +0.07 | +14.89% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 20, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 4, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 10, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 7, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Mar 22, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 13, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
About Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for kidney transplantation, xenotransplantation, and liver transplantation. The company has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- eledon.com
News
Eledon Pharma Reports Improved Quality Of Life And Reduced Symptom Burden With Tegoprubart In Kidney Transplant Patients At ASN Kidney Week 2026 
Eledon Presents Updated Long-Term Data From Phase 2 BESTOW Clinical Program Evaluating Tegoprubart In Patients Undergoing Kidney Transplantation At International Congress Of The Transplantation Society 
Eledon Pharmaceuticals Says FDA Grants Fast Track Designation To Tegoprubart For Prevention Of Rejection In Kidney Transplantation; Expects To Initiate Phase 3 LEGACY Study In Q4 2026 
Eledon Pharma Q2 EPS $(0.27) Misses $(0.16) Estimate 
This Fortinet Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Tuesday 
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday 
Rodman & Renshaw Initiates Coverage On Eledon Pharmaceuticals with Buy Rating, Announces Price Target of $12 
12 Health Care Stocks Moving In Friday's After-Market Session - NewcelX Completes Type B Pre-IND Meeting With FDA; Administration Provided Constructive Feedback And Alignment On Proposed Strategy
- Natera Partners With Eledon Pharmaceuticals To Incorporate Its Prospera Kidney Transplant Assessment Test Into Eledon’s Planned Phase 3 Clinical Trial Of Tegoprubart, An Investigational Therapy Designed To Prevent Organ Rejection In Kidney Transplantation
Your note
Sign in to keep a note on ELDN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BVF PARTNERS L P | Beneficial Owner of more than 10% of a Class of Security | Purchase | May 8, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| BVF Inc. | 10.53% | 6,293,282 | 26.37M | Sep 29, 2024 |
| Armistice Capital, LLC | 3.96% | 2,364,000 | 9.91M | Sep 29, 2024 |
| Vanguard Group Inc | 2.62% | 1,565,487 | 6.56M | Sep 29, 2024 |
| Schonfeld Strategic Advisors Llc | 2.51% | 1,500,000 | 6.29M | Sep 29, 2024 |
| Zimmer Partners, Lp | 2.40% | 1,434,727 | 6.01M | Sep 29, 2024 |
| Sphera Funds Management Ltd. | 2.17% | 1,297,321 | 5.44M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.93% | 1,152,398 | 4.83M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.64% | 385,138 | 1.61M | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.37% | 220,431 | 923.61K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.15% | 87,894 | 368.27K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.09% | 56,617 | 237.22K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.08% | 48,878 | 204.80K | Oct 30, 2024 |